Please assess the completion status of the following clinical trial:

Trial Title: Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between the age of 3 and 60 years, inclusive.~* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.~* Presence of acute uncomplicated P. falciparum mono-infection confirmed by:~  1. Fever, as defined by axillary/tympanic temperature ≥ 37.5°C or oral/rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and,~ 2. Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/μl of blood.~* Written informed consent, in accordance with local practice, provided by patient and/or parent/guardian/spouse.~* Ability to swallow oral medication.~Exclusion Criteria:~* Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.~* Mixed Plasmodium infection.~* Severe vomiting or severe diarrhoea.~* Known history or evidence of clinically significant disorders.~* Presence of significant anaemia, as defined by Hb \<8 g/dL.~* Presence of febrile conditions caused by diseases other than malaria.~* Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, lumefantrine or artesunate or other artemisinins.~* Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or hypomagnesaemia.~* Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by a positive urine test.~* Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.~* Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprol, imipramine, amitriptyline, clomipramine).~* Received an investigational drug within the past 4 weeks.~* Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen. (HBsAg) or Hepatitis C antibody (HCV Ab).~* Known seropositive HIV antibody.~* Liver function tests \[ASAT/ALAT levels\] \>2.5 times the upper limit of normal range.~* Known significant renal impairment as indicated by serum creatinine \>1.4 mg/dL.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PA group (Type: EXPERIMENTAL): Pyronaridine artesunate (PA)
- AL group (Type: ACTIVE_COMPARATOR): Arthemether lumefantrine (AL)

Based on this trial design, predict the completion outcome and termination type (if applicable).